Service Area
Product Pipeline
Our products are specifically directed against hematologic malignancies. These include therapeutic antibodies which can precisely block immune checkpoint proteins and enhance immune cell function against cancer cells. In addition, we develop small molecule inhibitors against oncogenic kinases which are overexpressed or hyper activated in acute myeloid leukemia (AML).
1492
Laboratories in 100+ states
152
Laboratory specialists
1022
Material collection points
24332
Patients diagnosed in 2022
Broad Applicability Across the Hematology Spectrum
Our drug candidates have been designed to provide safe single agent efficacy in multiple adjacent indications, as well as enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
- Tuspetinib (formerly HM43239): Myeloid Kinase Inhibitor (MKI) for AML
- Luxeptinib: Lymphoid Kinome Inhibitor (LKI) for B-NHL
- Luxeptinib: Myeloid Kinome Inhibitor (MKI) for AML/MDS
Our Clinical Trials in Hematologic Malignancies
Currently, we have three ongoing clinical trials with our investigational drug candidates:
Tuspetinib: Phase 1/2
Tuspetinib is in a Phase 1/2 clinical trial for the treatment of patients with relapsed or refractory AML
Luxeptinib: Phase 1a/b
Luxeptinib is in a Phase 1a/b clinical trial for the treatment of patients with B-cell malignancies, including CLL and NHL, who have failed or are intolerant to the standard treatments available.
Luxeptinib: Phase 1a/b
Luxeptinib is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML and high risk MDS.Why Choose Us
High Quality Services
Nam eget dui vel quam sodales semper quis porttitor tortor.
Fast Working Process
Nam eget dui vel quam sodales semper quis porttitor tortor.
24/7 Customer Support
Nam eget dui vel quam sodales semper quis porttitor tortor.
We have Expert Team
Nam eget dui vel quam sodales semper quis porttitor tortor.
Contact Us
Meet Specialist
Venkata Lokesh Battula
Ph.D. Founder and Scientific Advisor
Venkata Lokesh Battula
Ph.D. Founder and Scientific Advisor
Venkata Lokesh Battula
Ph.D. Founder and Scientific Advisor
Venkata Lokesh Battula
Ph.D. Founder and Scientific AdvisorCustomer Feedback
BIoxlab is another theme that is beautiful and professinally constructed by the Developers. The price for the template is checp but not qualityh of product.what a bargain , This theme works for many types of web sites and seems to be durble dows nt break and it.
Darlene Robertson
Secretary of (FlaxStudio)
BIoxlab is another theme that is beautiful and professinally constructed by the Developers. The price for the template is checp but not qualityh of product.what a bargain , This theme works for many types of web sites and seems to be durble dows nt break and it.
Courtney Henry
CEO of (FlaxStudio)
BIoxlab is another theme that is beautiful and professinally constructed by the Developers. The price for the template is checp but not qualityh of product.what a bargain , This theme works for many types of web sites and seems to be durble dows nt break and it.
Kathryn Murphy
Manager of (FlaxStudio)
BIoxlab is another theme that is beautiful and professinally constructed by the Developers. The price for the template is checp but not qualityh of product.what a bargain , This theme works for many types of web sites and seems to be durble dows nt break and it.
Darlene Robertson
Programmer of (FlaxStudio)Looking for a best
lebatory Service
Call :832-271-0032
Blog & Article
10Aug
Laboratories used for scientific research take
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
10Aug
Four Ways to Fulfill Your Task
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
10Aug
How autophagy models in mice could
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
10Aug
Partnership to Increase COVID19 Testing Capacity
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
10Aug
Driving that Gene, Mutations Seen Spreading
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium
10Aug
Medication Concerns and COVID-19 Symptoms in
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium